Main Therapeutic Uses

Dicloduo Combi is a combination medicinal product primarily used for the symptomatic treatment of specific inflammatory and degenerative conditions affecting the musculoskeletal system. It is specifically formulated for patients who require relief from pain and inflammation when simpler therapeutic options are insufficient.

The medication is most commonly used to manage symptoms associated with:

• Rheumatoid arthritis: An autoimmune condition characterized by chronic joint inflammation.
• Osteoarthritis: A degenerative joint disease involving the breakdown of cartilage and underlying bone.
• Ankylosing spondylitis: A long-term type of arthritis that affects the spine and large joints.

Therapeutic Benefits of the Combination

Dicloduo Combi contains two active substances that work through different mechanisms to provide a dual therapeutic effect:

Anti-inflammatory and Analgesic Action

The first component belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Its primary role is to reduce the production of prostaglandins, which are chemicals in the body responsible for signaling pain and inducing inflammation. By lowering these levels, the medication helps to:

• Decrease joint swelling and tenderness.
• Improve physical mobility and functional capacity.
• Alleviate persistent pain associated with chronic inflammatory states.

Gastric Protection

The second component is a proton pump inhibitor (PPI). Its inclusion is designed to address a common side effect of NSAID therapy. This component works by reducing the amount of acid produced in the stomach, thereby protecting the lining of the digestive tract. The main benefits of this integration include:

• Reducing the risk of developing stomach or duodenal ulcers.
• Decreasing the likelihood of acid-related irritation or erosions in the gastrointestinal system.
• Providing a more tolerable treatment profile for patients who are at a higher risk of gastric complications while requiring long-term anti-inflammatory therapy.

Eligibility Map: Who can and Cannot Use Dicloduo Combi

Official regulatory guidelines define specific populations for whom Dicloduo Combi is approved, restricted, or strictly contraindicated. This fixed-dose combination, which contains the NSAID diclofenac, is primarily intended for adults who require anti-inflammatory treatment but are also at an increased risk of developing stomach or intestinal ulcers.

Eligibility Classification	Population Status
Approved Population	Adults only, particularly those with a defined risk of GI damage.
Contraindicated Populations	Patients with established severe heart failure (NYHA Class II-IV), ischaemic heart disease, or cerebrovascular disease. Also prohibited in patients with active or recurrent gastrointestinal ulceration/bleeding or a history of allergic reaction (asthma, urticaria) to any NSAID.
Organ Function Restriction	Strictly contraindicated in cases of severe hepatic or severe renal failure. Use in mild-to-moderate impairment requires caution and careful consideration.
Age Restriction	Not recommended for children and adolescents under 18 years due to a lack of established safety and efficacy data.
Pregnancy/Lactation	Contraindicated during the third trimester of pregnancy and not recommended for use while breastfeeding or during the first two trimesters.

Dicloduo Combi contains two active substances, diclofenac and omeprazole, and can interact with many other medicines. It is essential to inform your doctor or pharmacist of all medications, supplements, and herbal remedies you are taking.

Contraindicated Combination

• Nelfinavir (a medicine for HIV infection) must not be taken concurrently with Dicloduo Combi, due to the omeprazole component.

---

Combinations Increasing Risk of Side Effects

Concomitant use with the following medicines can increase the risk of side effects, particularly gastrointestinal bleeding or kidney problems:

• Other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), including selective COX-2 inhibitors, aspirin, ibuprofen, or naproxen.
• Anticoagulants (e.g., warfarin) and anti-platelet agents (e.g., clopidogrel) which thin the blood.
• Corticosteroids (e.g., prednisolone).
• Selective Serotonin Reuptake Inhibitors (SSRIs) for depression (e.g., fluoxetine, sertraline).
• Diuretics ('water tablets') and medicines for high blood pressure (e.g., ACE inhibitors, beta-blockers, angiotensin II receptor antagonists).
• Ciclosporin or tacrolimus (immunosuppressants).
• Lithium (for mood disorders) or methotrexate (for arthritis or cancer), as diclofenac may increase their concentration in the blood.

---

Other Notable Interactions

Omeprazole may reduce the effectiveness of certain drugs whose absorption depends on stomach acidity, such as atazanavir (for HIV) and some antifungals (e.g., ketoconazole). Omeprazole may also increase the concentration of medicines like diazepam (for anxiety) or phenytoin (for epilepsy). Colestipol/cholestyramine can decrease diclofenac absorption. Taking Dicloduo Combi with alcohol may also increase the risk of gastrointestinal side effects.

The Dicloduo Combi formulation achieves its pharmacodynamic profile through two distinct mechanistic actions: the inhibition of the cyclooxygenase pathway by Diclofenac and the inhibition of gastric acid secretion by Omeprazole.

Inhibition of the Cyclooxygenase Enzyme System (COX)

Diclofenac functions by targeting and limiting the activity of cyclooxygenase ( COX) enzymes, primarily COX-2. This enzymatic inhibition suppresses the conversion of arachidonic acid into prostaglandins, which are chemical mediators involved in localized pro-inflammatory signaling and thermoregulation. The resulting physiological consequence is the reduction in prostaglandin-mediated signaling within the local environment.

Irreversible Blockade of the Gastric Proton Pump

Omeprazole targets and irreversibly inhibits the H^+/ K^+- ATPase (the proton pump), a final enzyme system located in the gastric parietal cells responsible for the transport of hydrochloric acid. This focused mechanism directly limits the output of gastric acid, resulting in reduced acidity within the gastric lumen, a mechanism that operates independently of COX pathway modulation.

How to Use Dicloduo Combi (Diclofenac 75 mg / Omeprazole 20 mg)

This section outlines the administration instructions for Dicloduo Combi.

Administration and Dosage

Dicloduo Combi is administered for oral use.

Instruction	Detail
Dosing Regimen	Take one modified-release hard capsule per day.
Frequency	Once daily.
Preparation	The capsule must be swallowed whole with liquid.
Restriction	Do not chew or crush the capsule.

The principle for use is to apply the lowest effective dose for the shortest duration necessary to control symptoms. Treatment should be continued until the individual treatment goals are achieved and should be regularly evaluated.

Population-Specific Instructions

Population	Instruction
Children and Adolescents (under 18)	Not recommended due to a lack of data on safety and efficacy.
Elderly (over 65)	Use the lowest effective dose for the shortest possible duration.
Impairment	Contraindicated in patients with severe renal or hepatic impairment. Close monitoring is required for mild to moderate impairment.

Procedural Summary

1. Take one Diclofenac 75 mg/Omeprazole 20 mg modified-release hard capsule.
2. Swallow the capsule whole with liquid.
3. Take this dose once daily.
4. Avoid taking Dicloduo Combi with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Research Evidence: Overview of Studies for Dicloduo Combi

Evidence for Use in Chronic Inflammatory Joint Disorders

Research has explored this fixed-dose combination (FDC) in individuals with chronic joint conditions, including osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS), which are conditions marked by functional limitations. The primary evidence source includes large-scale Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluated the use of a non-steroidal anti-inflammatory drug (NSAID) alongside a gastroprotective medicine. Studies monitored outcomes related to physical discomfort and daily functioning or activity level as they related to these joint conditions.

Trials monitored and reported how patient symptoms evolved in the observed populations during the study period. Research examined outcomes related to physical discomfort and functional imbalance to understand symptom patterns in those receiving the combination. Studies report the symptom changes measured during these studies.

Study Focus on Gastrointestinal (GI) Safety and Risk Reduction

A key area of research was evaluated in trials specifically designed to look at the second component of this FDC: omeprazole, a component of the combination. These studies focused on the GI safety component, particularly in populations at high risk of developing side effects from the anti-inflammatory drug. The main study outcomes examined were related to the incidence of serious gastrointestinal events, such as ulcer formation or bleeding.

Research has examined patterns observed in the studies regarding the incidence of GI events in the populations examined. Research reports short-term changes in measured GI outcomes. However, the specific fixed-dose capsule was not directly tested in large, new clinical outcome trials; instead, regulatory assessment was based on bioequivalence studies confirming the FDC delivers the two components similarly to taking them separately, and extrapolation of established data from the free components and similar combination strategies.

What Remains Unclear or Under Study

There is limited information for long-term outcomes that would describe the stability of the observed patterns over many months or years of continuous use. Follow-up durations for the key GI safety outcomes were limited to the intermediate-term. Long-term effects for continuous daily use are not fully established, and the evidence does not provide complete long-term predictions.

The reliance on extrapolation for the final FDC product remains a primary limitation. Because the specific capsule was approved largely through bioequivalence and drawing from studies involving the separate components, dedicated, large-scale, long-term trials of the final fixed product are lacking. Subgroup findings, such as for patients who are at an extremely high risk of recurrent events, appear to indicate persistent risk, suggesting that evidence quality varies across studies based on the specific subgroup examined.

Common questions about Dicloduo Combi (FAQ)

Q: Can I stop taking Dicloduo Combi if my symptoms are relieved?

Stopping a prescribed medication, even when symptoms appear resolved, is generally discouraged. Abrupt discontinuation may be associated with a risk of symptom recurrence or adverse effects. Any changes to a medication regimen should be discussed with a healthcare provider.

Q: Does Dicloduo Combi make you gain weight?

The safety profile of Dicloduo Combi is established by regulatory bodies. According to clinical data, weight gain is not typically reported as a common side effect. Minor fluid retention is a possible, though uncommon, reported side effect. It is important for patients to continue following their healthcare provider’s recommendations regarding diet and exercise.

Q: How long does Dicloduo Combi take to work?

Dicloduo Combi contains components that begin to provide relief within hours of administration. However, the full therapeutic effect, as indicated in product labeling, may take several days of consistent dosing to be observed. Taking the medication at the same time each day helps maintain consistent blood levels. Patients should follow their prescription instructions for daily timing.

Dicloduo Combi must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Requirement	Official Instruction
Maximum Temperature	Do not store above 30, C
Moisture Protection	Keep the container tightly closed to protect from moisture
Child Safety	Keep out of the sight and reach of children

Stability and Disposal

For the product supplied in an HDPE bottle, the contents must be used within 1 month after first opening the container. Unused or expired Dicloduo Combi should not be disposed of via household waste or wastewater. Final disposal must follow local requirements for medicinal products to ensure proper environmental handling.